Kenvue Inc. is a pure-play consumer health company based in the United States, spun off from Johnson & Johnson and taken public in 2023. It develops, markets, and sells over-the-counter medicines, personal care, and skin health products through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its brand portfolio includes Tylenol, Motrin, Zyrtec, Benadryl, Listerine, Johnson's, Aveeno, Neutrogena, and Band-Aid. Kenvue sells primarily through mass retailers, pharmacies, grocery chains, e-commerce platforms, and healthcare professionals, reaching consumers in more than 165 countries, with North America and Europe among its largest markets. Revenue comes mainly from product sales of branded consumer health goods, supported by advertising and retail distribution. In 2025, Kimberly-Clark agreed to acquire Kenvue, with the transaction expected to close in the second half of 2026.

Piotroski F-Score

Beneish M-Score

Operating Margin %

Dividend Payout Ratio